Death rattle: critical review and research agenda
|
|
- Andrew Chase
- 6 years ago
- Views:
Transcription
1 Support Care Cancer (2014) 22: DOI /s REVIEW ARTICLE Death rattle: critical review and research agenda Sebastiano Mercadamte Received: 19 September 2013 /Accepted: 31 October 2013 /Published online: 20 November 2013 # Springer-Verlag Berlin Heidelberg 2013 Abstract The aim of this critical review was to assess the literature regarding the treatment of death rattle at the end of life to provide an update information regarding this difficult issue. To provide suggestions for future research agenda, the approach was analytic and based on clinical considerations, rather than on raw evidence only. Both published and unpublished reports from an extensive search of electronic databases. Any randomized-controlled trial or clinical reports with a significant number of patients was considered. Eleven reports fulfilled the inclusion criteria in this systematic review. Four controlled studies, four comparative audits, and three clinical reports with a significant number of patients were selected. Despite anticholinergic or antimuscarinic medications are the drugs of choice in practice, there is a lack of supporting evidence for the use of anticholinergics to treat death rattle. Regardless of the methodological limitations of existing studies, an a priori observation was missed. Most studies were performed with the intent to treat rather than to prevent death rattle. However, from a pharmacological perspective, anticholinergic agents are unable to reduce the secretions once they are formed, but may just limit a further production. In conclusion, studies on the use of antisecretive agents provided only minor evidence of efficacy, ultimately raising questions about the routine inclusion of anticholinergic treatment in end of life pathways for the treatment of death rattle. However, this observation could be confuted by the use of these same drugs used earlier in a prophylactic perspective, in the context of a comprehensive management of the dying patients. S. Mercadamte (*) Anesthesia & intensive Care & Pain Relief and Supportive Care, La Maddalena Cancer Center, Via San Lorenzo 312, Palermo, Italy 03sebelle@gmail.com S. Mercadamte terapiadeldolore@lamaddalenanet.it Keywords Death rattle. Bronchial secretions. End of life. Palliative care. Anticholinergics Introduction Research in palliative care is notoriously difficult. There is a need to implement the evidence base underpinning the practice of palliative care and improve the care of dying patients. However, there are clinical conditions which are quite difficult to explore, due to contingent clinical needs and ethics that render unfit patients to be included in traditional randomized clinical trials designed for providing evidence for a treatment. Death rattle frequently occurs in the dying patient, occurring in 23 to 92 % of people who are dying [1 4]. Death rattle is due to an accumulation of secretions in the pharynx and/or airways [1], in absence of effective reflexes in swallowing and coughing. Although the exact patients perception is difficult to evaluate in terms of suffering, relatives are often distressed in hearing the sound of death rattle, regardless of effective communication in uncovering interpretation of death rattle and dispelling unwarranted fears [5]. Given the relevance of this sign from different point of views, it is worthwhile of interest but information is lacking. In a large quality register cross-sectional longitudinal study during a period of 3 years, % of dying patients were prescribed as needed medication for death rattle [6]. Anticholinergic or antimuscarinic medications are the drugs of choice in practice, even in the absence of patient distress, despite there being no conclusive evidence to suggest that any drug is superior to placebo. Recently, it has been suggested that there is a lack of supporting evidence for the use of anticholinergics to treat death rattle [7]. A recent focus group raised questions about the routine inclusion of anticholinergic treatment in end of life pathways for the treatment of death rattle. Physicians and nurses felt to be pressed to administer anticholinergics, and drugs were given in order to be seen to do something, although the benefit in terms of therapeutic response was
2 572 Support Care Cancer (2014) 22: considered minimal, while monitoring of adverse effects was considered to be problematic [8]. Finally, anticholinergic drugs are often recognized to be associated with unpleasant side effects such as urinary retention and dry mouth for patients who are probably unable to report symptoms. In the setting of an imminent death, however, it is difficult for staff members to not intervene and controlled studies could be of concern from the ethical point of view. The aim of this critical review was to assess the literature regarding the treatment of death rattle at the end of life to provide an update information regarding this difficult issue. To provide suggestions for future research agenda, the approach was analytic and based on clinical considerations, rather than on raw evidence only. Methods Both published and unpublished reports from an extensive search of electronic databases, including PUBMED, were collected from January 1990 to April MEDLINE, CANCERLIT, and EMBASE were also consulted. A freetext search method was used including the following words: death rattle and/or noisy breathing. Hand searching of relevant journals, and European conference proceedings, were also considered. The references of all relevant reports and review articles were searched for additional trials. Any randomized-controlled trial or clinical reports with a significant number of patients was considered. Case reports, letters, and no-english literature were excluded. Results Fifty-five hits were found, and 11 reports fulfilled the inclusion criteria in this systematic review. Four controlled studies, four comparative audits, and three clinical reports with a significant number of patients were selected. In the largest study of 333 patients, hyoscine hydrobromide (HH), atropine (AT), and hyoscine butylbromide (HB) were compared [9]. In another large randomized-controlled study, AT was compared with placebo in 137 patients [10]. One small crossover comparative study assessed the efficacy of octreotide (OC) and HH. About half of randomized patients did not receive the medication before dying, and only ten patients were analyzed [11]. Another small study of 13 patients compared HH and glycopyrronium (GL) [12]. Four audits of antisecretive drugs have been found. The first one was an audit of the use of three clinical guidelines, each relying on a different anticholinergic drug for the first line and included HH, HB, and GP [13]. A comparative nonrandomized study was performed in two phases, assessing the efficacy of HB in 108 patients and then GL in 62 patients [14]. In a similar design performed in two phases, 77 patients with death rattle were compared with a matched cohort of 36 patients previously treated with HH [15]. This group of patients had already been reported in a previous study [4]. Three clinical reports of more than 20 patients were collected. Forty-four patients were treated with HH, as a part of a comprehensive treatment of the last hours of life [3]. A retrospective series of 25 patients treated with HH was reported [2]. In a retrospective chart review, sublingual atropine 1 % ophthalmic drops were used in 22 patients for the management of death rattle in dying patients [16]. The characteristics of these studies are represented in Table 1. Discussion Death rattle predicts death within 48 h for 75 % of patients [2]. Despite death rattle has been reported to be a frequent and often predictable sign [1, 2, 17], scientific research provided poor evidence and uncertain data. In the selected retrospective and prospective series, audits, and randomized controlled studies, pharmacological interventions were evaluated with the intent to decrease pharyngeal secretion and the consequent death rattle in dying patients. Hyoscine butylbromide and hyoscine hydrobromide Hyoscine hydrobromide and HB have been used for years. HB has been proposed alternately to HH because it does not produce central effects due to its inability to pass through the blood brain barrier. They showed different efficacy rates ranging %. The large differences found in the literature are explained by the different doses, modalities of administration, timing, and study designs [2, 4, 9, 11 15, 18]. Atropine Three papers assessed AT for the management of death rattle. In 19 of 22 patients (86 %), a reduction or resolution of death rattle was documented with sublingual AT [16]. In a randomized-controlled study with a large number of patients, no differences in efficacy were observed between AT, HB, and HH [9]. AT 1 mg sublingually was found to be ineffective in reducing noisy secretions. One hundred thirty-seven participants were randomized to AT or placebo. No differences were foundbetween2and4hafterdrugadministration[9]. AT was well tolerated [16]. Similar to placebo, heart rate increased slightly but not significantly [9]. No relevant differences in adverse effects between AT, HB, and HH were found [10].
3 Support Care Cancer (2014) 22: Table 1 Characteristics of studies selected: design, treatments, and doses (mg), efficacy (percentage, as reported by authors), palliative sedation (PS, percentage), hydration withdrawal (HW, percentage), and pharyngeal suction (FS, percentage) Authors Design Pts Treatments Efficacy (%) PS (%) HW (%) FS (%) Hughes et al. (2000) Pro 37 HH NA NA NA HB GL Morita et al. (2000) Pro 44 HH Back et al. (2001) Pro 108 HH * 81 c NA NA 63 GL * 91 c Wildiers and Menten (2002) Ret 25 HH 0.25 a b 72 8 Fluid restriction NA Hughel et al. (2006) Pro 77 GL a b 58 NA NA NA Kaas and Ellershaw (2003) Ret 36 HH 0.4 a b NA NA NA Clark et al. (2008) RC-DB-CO 10 HH 0.4 OC unconscious 80 NA OC 0.2 HH 0.4 Likar et al. (2008) RC-DB 13 HH 0.5 GL>HH unconscious NA NA GL 0.4 Wildiers et al. (2009) RC-DB 303 AT 3 a 3 b NA NA NA HH 0.25 a 1.5 b HB 20 a 60 b Protus et al (2012) Ret 19 AT NA NA 77 Heisler et al. (2013) RC-DB 137 AT 1 37 NA NA NA Placebo 41 Pro prospective, Ret retrospective, RC randomized controlled, DB double blind, CO crossover, HH hyoscine hydro bromide, HB hyoscine butylbromide, GL glycopirrolate, AT atropine, OC octreotide, NA not applicable a bolus b continuous infusion c based on continuous infusion of midazolam Glycopyrrolate Glycopyrrolate has been considered as an alternative drug to HH, because of the costs, a favorable adverse effect profile, and a slower onset of action. Contrasting data exist on efficacy, use of sedatives, or levels of agitation [13, 15, 16]. Comparative studies were not performed in parallel, but in different phases with differences in the prevalence of death rattle collected in different phases and with different design, prospective and retrospective, provided equivocal information with different timing and outcomes between GL and HH, regardless the doses used [14, 15]. Missing data may be different in the two phases of data collection. This information is more likely to be considered as audit of the units rather than real comparative studies. Regardless of the cost, data presented are not convincing. A very small controlled study showed that GL produced a significant decrease in death rattle intensity at various time points in comparison with HH [12]. The use of GL to prevent hemodynamic or central effects in the context of the dying patient seems to be unpractical, given that most patients are neurologically deranged or sedated, and tachycardia is one the predictive signs of imminent death [19]. The condition of approaching death cannot allow a distinction between the burden of symptoms present at the end of life and drug-induced adverse effects, and several drugs are concomitantly given with different indications. Finally, there are no detailed pharmacokinetic data on subcutaneous administration [20]. Octreotide Octreotide has been hypothesized to have antisecretory effects on the airways. Ten patients were randomized to receive OC 200 mcg subcutaneously or HH 400 mcg. If subsequent treatment was needed, the other medication was administered. The subsequent treatment was at nurse s discretion. Intensity of noise breathing did not change with both treatments [11]. Other aspects are worthwhile of analysis, other than the pharmacological treatment. Traditionally, the use of hydration has been though not to be benefit the terminally ill, particularly because it could increase peripheral edema, pleural effusion, ascites, and death rattle. Consequently, non-hydration has been suggested to reduce respiratory secretions. This issue has never been elucidated. In a large prospective observational study, in which the decision to hydrate or not was based on physicians individual decision, non-hydration did not prevent the production of bronchial secretions in comparison with hydration group, while peripheral edema, pleural effusion,
4 574 Support Care Cancer (2014) 22: and ascites were less likely to occur [18]. More recently, in a multicenter national study, the decision to hydrate or not was based on specific guidelines. The prevalence of bronchial secretion was reported to be higher in the large-volume hydration group, although no specific data were provided [21]. Thus, the practice of non-hydration to prevent or reduce bronchial secretions remains unclear. General comments and future research agenda In consideration of the difficulties in assessing dying patients, the definition of effectiveness varied widely or was not clearly stated a priori [2, 9, 14]. Of interest, the noise cannot due only to pharyngeal secretions, but also to the tongue in patients with a low level of consciousness, as suggested by the observation that brain and lung tumors were independent risk factors for development of death rattle [3, 4]. This is confirmed by the observation that the conscious level was compromised in 87 % of the patients developing death rattle [3]. Non-pharmacological care, including head repositioning, may be helpful in these circumstances. A more appropriate term like secretive noise should be applied to differentiate between mechanical rumors and accumulation of secretions. There are some aspects to be considered. A prolonged dying phase was a significant factor for developing death rattle [1, 4], and when treatment is started early or in patients with a low rattle score intensity, the treatment is much more effective. On the other hand, patients with higher baseline rattle scores die earlier [9]. Regardless of the methodology of the studies, justified by the difficult setting and clinical situation, assessment tools, dosing, and timing for efficacy measurement, as well as missing observations, were quite variable or limited in time. In some cases, evaluation was performed after few hours only. Of interest, the obvious consideration that anticholinergic drugs are unable to remove existent secretions and may only prevent a further production and consequent accumulation rather than eliminating the existing ones has been rarely taken into consideration in all the studies. In fact, drugs have been used to treat noisy secretion rather than preventing [17]. A prophylactic treatment against death rattle once patients are considered in the dying phase has been advocated for a better efficacy of treatment [4] or possibly before starting palliative sedation, which inevitably is associated with a loss of reflexes for coughing and swallowing [22]. Alternately, gentle suction of pharyngeal secretion should precede the start of an anticholinergic treatment [17]. Despite this obvious observation, all the available studies have been performed in patients with formed secretions which cannot be managed anymore with anticholinergic drugs, able only to reduce the formation of new secretions, explaining a lack of effects or the poor differences between drugs and placebo. In this perspective, if anticholinergic drugs are administered as early as possible in the context of imminent death, before starting palliative sedation, or after gentle aspiration of existing secretions, it is quite obvious that statistical changes from a lower baseline measurement may be less evident, and the avoidance of the occurrence of death rattle should be the outcome. Finally, most studies provided limited data regarding the context of the dying patients, for example, palliative sedation or level of hydration. Future studies should assess whether the benefits of reducing the prevalence and severity of death rattle outweigh of adding a drug even in patients who potentially might not need it, in the context of a comprehensive management of the last hours of life. In conclusion, studies on the use of antisecretive agents provided only minor evidence of efficacy, ultimately raising questions about the routine inclusion of anticholinergic treatment in end of life pathways for the treatment of death rattle [8]. However, this observation could be confuted by the use of these same drugs used earlier in a prophylactic perspective, in the context of a comprehensive management of the dying patients. Conflict of interest References None 1. Bennett M, Lucas V, Brennan M, Hughes A, O'Donnell V, Wee B (2002) Association for Palliative Medicine's Science Committee. Using anti-muscarinic drugs in the management of death rattle: evidence-based guidelines for palliative care. Palliat Med 16: Wildiers H, Menten J (2002) Death rattle: prevalence, prevention and treatment. J Pain Symptom Manage 23: Morita T, Tsunoda J, Inoue S et al (2000) Risk factors for death rattle in terminally ill cancer patients: a prospective exploratory study. Palliat Med 14: Kaas RM, Ellershaw J (2003) Respiratory tract secretions in the dying patient: a retrospective study. J Pain Symptom Manage 26: Wee B, Coleman P, Hillier R et al (2006) The sound of death rattle. II: how do relative interpret the sound. Palliat Med 20: Martinsson L, Fürst CJ, Lundström S, Nathanaelsson L, Axelsson B. (2012) Registration in a quality register: a method to improve end-oflife care a cross-sectional study. BMJ Open Aug 30;2 (4) 7. Wee B, Hillier R (2008) Interventions for noisy breathing in patid review of management. Cochrane Database Syst Rev 1, CD Hirsch CA, Marriott JF, Faull CM (2013) Influences on the decision to prescribe or administer anticholinergic drugs to treat death rattle: a focus group study. Palliat Med 27: Wildiers H, Dhaenekint C, Demeulenacre P et al (2009) Atropine, hyoscine butylbromide, or scopolamine are equally effective for the treatment of death rattle in terminal care. J Pain Symptom Manage 38: Heisler M, Hamilton G, Abbott A et al (2013) Randomized doubleblind trial of sublingual atropine vs. placebo for the management of death rattle. J Pain Symptom Manage 45: Clark K, Currow DC, Agar M et al (2008) A pilot phase II randomized, cross-over, double-blind, controlled efficacy study of octreotide versus hyoscine hydrobromide for control of noisy breathing at the end of life. J Pain Palliat Care Pharmacother 22:
5 Support Care Cancer (2014) 22: Likar R, Rupacher E, Kager H et al (2008) Comparing the efficacy of glycopirronium bromide and scopolamine hydro bromide in patients with death rattle. A prospective randomized study. Mid Eur J Med 120: Hughes A, Wilcock A, Corcoran R et al (2000) Audit of three antimuscarinic drugs for managing retained secretions. Palliat Med 14: Back IN, Jenkins K, Blower A et al (2001) A study comparing hyoscine hydrobromide and glycopyrrolate in the treatment of death rattle. Palliat Med 15: Hughel H, Ellershaw J, Gambles MR (2006) Espiratory tract secretions in the dying patient: a comparison between glycopyrronium and hyoscine hydrobromide. J Palliat Med 8: Protus BM, Grauer PA, Kimbrel J (2012) Evaluation of atropine 1 % opthalmic solution administered sublingually for the management of terminal respiratory secretions. Pall Med 30: Mercadante S, Villari P, Ferrera P (2011) Refractory death rattle: deep aspiration facilitates the effects of antisecretory agents. J Pain Symptom Manage 41: Morita T, Hyodo I, Yoshomi T et al (2005) Association between hydration volume and symptoms in terminally ill cancer patients with abdominal malignancies. Ann Oncol 16: Mercadante S, Valle A, Porzio G et al (2011) How do cancer patients receiving palliative care at home die? A descriptive study. J Pain Symptom Manage 42: Prommer E (2013) Anticholinergics in palliative medicine: an update. Am J Hosp Pall Med 30: Yamaguchi T, Morita T, Shinjo T (2012) Effect of parenteral hydration therapy based on the Japanese National Clinical Guideline on quality of life, discomfort, and symptom intensity in patients with advanced cancer. J Pain Symptom Manage 43: Mercadante S, Intravaia G, Villari P et al (2009) Controlled sedation for refractory symptoms in dying patients. J Pain Symptom Manage 37:771 9
The Death Rattle Dilemma
2.5 ANCC Contact Hours The Death Rattle Dilemma Flannery Fielding, MS, NP, ACHPN ƒ Carol O. Long, PhD, RN, FPCN, FAAN Death rattle, defined as the noise created by the flow of air through secretions in
More informationIncidence and aetiology:
A pilot randomised cross-over double blinded controlled efficacy study of Octreotide versus hyoscine hydrobromide in controlling respiratory secretions at the end of life Katherine Clark, David Currow,
More informationAtropine, Hyoscine Butylbromide, or Scopolamine Are Equally Effective for the Treatment of Death Rattle in Terminal Care
124 Journal of Pain and Symptom Management Vol. 38 No. 1 July 2009 Original Article Atropine, Hyoscine Butylbromide, or Scopolamine Are Equally Effective for the Treatment of Death Rattle in Terminal Care
More informationB.C. INTER-PROFESSIONAL PALLIATIVE SYMPTOM MANAGEMENT GUIDELINES
B.C. INTER-PROFESSIONAL PALLIATIVE SYMPTOM MANAGEMENT GUIDELINES Copyright BC Centre for Palliative Care. 2017. 300-601 Sixth St. New Westminster, B.C. V3L 3C1. office@bc-cpc.ca please see Introduction
More informationRespiratory Secretions. Care in the last 72 hours of life Paul Tait, pharmacist
Respiratory Secretions Care in the last 72 hours of life Paul Tait, pharmacist 50% Why? Inability to swallow & clear secretions Ineffective cough Reduced consciousness Pooling of secretions in the throat
More informationRegional Palliative Care Services
Page 1 September 2018 - Issue 43 Regional Palliative Care Services In This Issue: Respiratory Congestion Northern Lights in Palliative Care Featuring: Jessica Fitterer, LPN Educational Opportunities Webinars
More informationGuidelines: EOLC Symptom Control for Patients with Normal Renal Function (in Wandsworth)
Guidelines: EOLC Symptom Control for Patients with Normal Renal Function (in Wandsworth) Policy Number : DC020 Issue Date: October 2014 Review date: October 2016 Policy Owner: Head Community Services Monitor:
More informationCare in the Last Days of Life
Care in the Last Days of Life Introduction This guideline is an aid to clinical decision making and good practice in person-centred care for patients who are deteriorating and at risk of dying. The patient
More informationThe last days of life in hospital and at home
The last days of life in hospital and at home Beaumont Multi-disciplinary Palliative Care Study Day 28/9/2017 Dr Sarah McLean Consultant in Palliative Medicine St Francis Hospice Beaumont Hospital Overview
More informationRenal Palliative Care Last Days of Life
Renal Palliative Care Last Days of Life Introduction This guideline is an aid to clinical decision-making and good practice for patients with stage 4-5 chronic kidney disease (egfr
More informationManaging Respiratory Symptoms - Breathlessness, Cough and Secretions. Dr Laura Healy. Palliative Medicine Registrar, Beaumont Hospital.
Managing Respiratory Symptoms - Breathlessness, Cough and Secretions. Dr Laura Healy. Palliative Medicine Registrar, Beaumont Hospital. Things to consider: 1. Very common symptoms. 2. Can occur in any
More informationPalliative Sedation in Patients with Advanced Cancer Followed at Home: A Systematic Review
754 Journal of Pain and Symptom Management Vol. 41 No. 4 April 2011 Review Article Palliative Sedation in Patients with Advanced Cancer Followed at Home: A Systematic Review Sebastiano Mercadante, MD,
More informationTarget audience: The target audience for this guidance are: GPs Care home managers and nurses, District nurses, and Specialist Palliative Care teams.
Anticipatory medication guidance for the last days of life for frail older people being care for in care homes who do not have Specialist Palliative Care needs Purpose of guidance: The purpose of this
More informationHydration at the End of Life:
Hydration at the End of Life: A systematic literature review and audit of current practice November 12 th 2015 Dr Alison Coackley- Consultant in Palliative Medicine, Clatterbridge Cancer Centre Dr Catherine
More informationPatients and Relatives Perceptions About Intravenous and Subcutaneous Hydration
354 Journal of Pain and Symptom Management Vol. 30 No. 4 October 2005 Original Article Patients and Relatives Perceptions About Intravenous and Subcutaneous Hydration Sebastiano Mercadante, MD, Patrizia
More informationSyringe driver in Palliative Care
Syringe driver in Palliative Care Introduction: Syringe drivers are portable, battery operated devices widely used in palliative care to deliver medication as a continuous subcutaneous infusion over 24
More informationTREATING RESPIRATORY SYMPTOMS IN PEDIATRIC PALLIATIVE CARE: Objectives 10/23/18 FROM DYSPNEA TO NOISY BREATHING
TREATING RESPIRATORY SYMPTOMS IN PEDIATRIC PALLIATIVE CARE: FROM DYSPNEA TO NOISY BREATHING Kris Catrine, MD, FAAP, HMDC October 24, 2018 Objectives Discuss pathophysiology of common respiratory symptoms
More informationDeath rattle after withdrawal of mechanical ventilation: Practical and ethical considerations
Intensive and Critical Care Nursing (2006) 22, 214 219 ORIGINAL ARTICLE Death rattle after withdrawal of mechanical ventilation: Practical and ethical considerations Erwin J.O. Kompanje Department of Intensive
More informationImplementing the recommendation on medication management and symptom control
Implementing the recommendation on medication management and symptom control Mike Grocott Professor of Anaesthesia and Critical Care Medicine University of Southampton Consultant in Critical Care Medicine
More informationPAIN MANAGEMENT Patient established on oral morphine or opioid naive.
PAIN MANAGEMENT Patient established on oral morphine or opioid naive. Important; It is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationWaterloo Wellington (WW) Symptom Management Guideline for the End of Life (EOL) Medication Order Set for Long Term Care (LTC)
Waterloo Wellington (WW) Symptom Management Guideline for the End of Life (EOL) Medication Order Set for Long Term Care (LTC) May 2018 THE WATERLOO WELLINGTON SYMPTOM MANAGEMENT GUIDELINE FOR THE END OF
More informationBREATHLESSNESS MANAGEMENT
Guideline Name: Breathlessness BACKGROUND Breathlessness is a common symptom in patients with cancer, end-stage heart failure and end-stage chronic obstructive pulmonary disease (COPD). There are many
More information1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER
1. GUIDELINES FOR THE MANAGEMENT OF AGITATION IN ADVANCED CANCER 1.1 GENERAL PRINCIPLES There are many causes of agitation in palliative care patients, which makes recommendations for treatment difficult.
More informationPAIN MANAGEMENT Person established taking oral morphine or opioid naive.
PAIN MANAGEMENT Person established taking oral morphine or opioid naive. Important; it is the responsibility of the prescriber to ensure that guidelines are followed when prescribing opioids. Every member
More informationMND Just in Case kit Information for GPs
MND Just in Case kit Information for GPs What is the MND Just in Case kit? 2 Motor neurone disease (MND) is a progressive and terminal disease that results in degeneration of the motor neurones in the
More informationPattern and characteristics of advanced cancer patients admitted to hospices in Italy
Support Care Cancer (2013) 21:935 939 DOI 10.1007/s00520-012-1608-3 ORIGINAL ARTICLE Pattern and characteristics of advanced cancer patients admitted to hospices in Italy Sebastiano Mercadante & Alessandro
More informationPalliative Care Pearls: What Works, What Doesn t
: Steven Pantilat, MD Kates-Burnard and Hellman Distinguished Professor of Palliative Care Director, Palliative Care Program and Palliative Care Quality Network Department of Medicine University of California,
More informationSYMPTOM CONTROL MEDICATION & THE DYING PERSON LITERATURE REVIEW, & DRAFT NEW STANDARDS & GUIDELINES
SYMPTOM CONTROL MEDICATION & THE DYING PERSON LITERATURE REVIEW, & DRAFT NEW STANDARDS & GUIDELINES 27 TH NOVEMBER 2014 SYMPTOM CONTROL MEDICATION & THE DYING PERSON GUIDELINE DEVELOPMENT GROUP RUTH CLARK
More informationGuidelines for the management of agitation in the last weeks of life
Guidelines for the management of agitation in the last weeks of life 14.09.17 Overview 1. Aim 2. Literature Review 3. Current Standards 4. Audit Results 5. Patient Representative Input 6. Proposed New
More informationRestlessness Emotional support Self care
Comfort Airway Restlessness Emotional support Self care MED 12412 9/12 City of Hope Department of Supportive Care Medicine 1500 Duarte Road Duarte, CA 91010 August 2012 The following are recommendations
More informationAlgorithms for Symptom Management. In End of Life Care
Algorithms for Symptom Management In End of Life Care The Use of Drugs Beyond Licence (off label) -The Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK regulates the activity of the
More informationPalliative Care Impact Survey
September 2018 Contents Introduction...3 Headlines...3 Approach...4 Findings...4 Which guideline are used...4 How and where the guidelines are used...6 Alternative sources of information...7 Use of the
More informationInpatient Palliative Medicine Update
Inpatient Palliative Medicine Update David Dupere MD, FRCPC Head, Division of Palliative Medicine Department of Medicine QEII Health Sciences Centre Halifax, Nova Scotia Disclosures Book chapter in Compendium
More informationPRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT
PRESCRIBING GUIDELINES FOR SYMPTOM MANAGEMENT IN THE DYING PATIENT A collaboration between: St. Rocco s Hospice, Bridgewater Community Healthcare NHS Trust, NHS Warrington Clinical Commissioning Group,
More informationRenal Prescribing at End of Life Guidance for Anticipatory prescribing for patients in renal failure (egfr<30) at the end of life
Guidance for Anticipatory prescribing for patients in renal failure (egfr
More informationSafety and Effectiveness of Intravenous Morphine for Episodic Breakthrough Pain in Patients Receiving Transdermal Buprenorphine
Vol. 32 No. 2 August 2006 Journal of Pain and Symptom Management 175 Original Article Safety and Effectiveness of Intravenous Morphine for Episodic Breakthrough Pain in Patients Receiving Transdermal Buprenorphine
More informationTo sleep or not to sleep? PALLIATIVE SEDATION FOR REFRACTORY SYMPTOMS
To sleep or not to sleep? PALLIATIVE SEDATION FOR REFRACTORY SYMPTOMS What is it? Intentional lowering of awareness to mitigate the experience of suffering at the end of life (AAHPM) Can include sedating
More informationINTEGRATED CARE PATHWAY (ICP) FOR THE DYING ADULT
INTEGRATED CARE PATHWAY (ICP) FOR THE DYING ADULT PLEASE INFORM THE PALLIATIVE CARE TEAM ON COMMENCEMENT OF THIS ICP (EXT 8958) ICP Start Date Patient s Name. Ward. Consultant.. Named Specialist Nurse
More informationCLINICAL GUIDELINES FOR END OF LIFE CARE MEDICATIONS IN LONG TERM CARE HOMES
CLINICAL GUIDELINES F END OF LIFE CARE MEDICATIONS IN LONG TERM CARE HOMES OPENING STATEMENT: Insert Facility Name is committed to providing effective end-of-life symptom management to all residents. Symptom
More informationEnd Stage Liver Disease Regional Audit Casenote Survey
1. This questionnaire is an audit of clinical documentation of patients who have died of end stage liver disease. If you have any questions about how this form should be completed please contact Dr Grace
More informationSupportive Care. End of Life Phase
Supportive Care End of Life Phase Guidelines for Health Care Professionals In the care of patients with established renal failure who are in the last days of life References: Chambers E J (2004) End of
More informationEnd-of-life care in oxygen-dependent COPD and cancer: a national population-based study.
End-of-life care in oxygen-dependent COPD and cancer: a national population-based study. Ahmadi, Zainab; Lundström, Staffan; Janson, Christer; Strang, Peter; Emtner, Margareta; Currow, David C; Ekström,
More informationSymptom Control in Heart Failure. Dr Claire L Hookey
Symptom Control in Heart Failure Dr Claire L Hookey Heart Failure symptoms Class III/IV CHF, mean 67.1 years, mean EF 22.3% Most prevalent symptoms:- lack of energy (66%) dry mouth (62%) shortness of breath
More informationApproach to symptom control near the end-of-life
Approach to symptom control near the end-of-life 18 Sept 2011 Dr Alethea Yee Senior Consultant, Department of Palliative Medicine National Cancer Centre,Singapore What is end of life? No precise definition
More informationComfort Measures: Practical Care of the Dying Cancer Patient
Cleveland Clinic Palliative Medicine Grand Rounds Comfort Measures: Practical Care of the Dying Cancer Patient American Journal of Hospice & Palliative Medicine 27(7) 488-493 ª The Author(s) 2010 Reprints
More informationMMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life
MMG035 Symptom Management Guidelines for a Person thought to be in the Last Few Days and Hours of Life The following pages are guidelines for the management of common symptoms for a person thought to be
More informationSedation in Palliative Care. Dr Katie Frew Consultant in Palliative Medicine Northumbria Healthcare NHS FT
Sedation in Palliative Care Dr Katie Frew Consultant in Palliative Medicine Northumbria Healthcare NHS FT Plan Background: sedation in palliative care Research outline Results Routine sedation Background:
More informationThe Quebec Palliative Sedation Guidelines. Rose DeAngelis, N, MSc(A), CHPCN (C)
The Quebec Palliative Sedation Guidelines Rose DeAngelis, N, MSc(A), CHPCN (C) CHPCA Conference September 2017 Conflict of Interest Statements There is no financial or in-kind support for this presentation.
More informationPain Rating Scale GG. PAIN MANAGEMENT (NEW 10) 1. Initiate General Patient Care.
GG. PAIN MANAGEMENT (NEW 10) 1. Initiate General Patient Care. 2. Presentation Pain may be present in many different conditions. Management of pain in the field can help to reduce suffering, make transport
More informationOxygen Use in Palliative Care Guideline and Flowchart
Oxygen Use in Palliative Care Guideline and Flowchart Reviewed: October 2013 Gippsland Region Palliative Care Consortium Clinical Practice Group Policy. Title Keywords Ratified Oxygen Use in Palliative
More informationChapter 7. Anticholinergic (Parasympatholytic) Bronchodilators. Mosby items and derived items 2008, 2002 by Mosby, Inc., an affiliate of Elsevier Inc.
Chapter 7 Anticholinergic (Parasympatholytic) Bronchodilators Clinical Indications for Use Indication for anticholinergic bronchodilator COPD maintenance Indication for combined anticholinergic and β-agonist
More informationThe last days of life Linda Magann CNC Palliative Care St George Hospital I m not afraid of dying, I just don t want to be there when it happens Woody Allen Palliative Care is an approach that improves
More informationADMINISTRATION OF PALLIATIVE SEDATION TO THE DYING PATIENT
ADMINISTRATION OF PALLIATIVE SEDATION TO THE DYING PATIENT PURPOSE To specify the circumstances under which the administration of Palliative Sedation is clinically and ethically appropriate for a dying
More informationPalliative care Non-malignant Respiratory Disease. Scott Davidson Queen Elizabeth University Hospital Glasgow
Palliative care Non-malignant Respiratory Disease Scott Davidson Queen Elizabeth University Hospital Glasgow UK deaths Place All deaths (%) Malignant (%) Hospital 66.5 55.5 Hospice 4.3 16.5 Other communal
More informationSupporting Last Days of Life Symptom Control Medication Guidance: Algorithm. Agitation & Anxiety
Agitation & Anxiety (Exclude or treat REVERSIBLE causes*) Patient is anxious / frightened, but lucid Patient is confused, agitated and / or hallucinating MIDAZOLAM 2.5-5mg s/c (Max total 24 hour dose of
More informationGastrointestinal obstruction Dr Iain Lawrie
Gastrointestinal obstruction Dr Iain Lawrie Consultant and Honorary Clinical Senior Lecturer in Palliative Medicine The Pennine Acute Hospitals NHS Trust / The University of Manchester iain.lawrie@pat.nhs.uk
More informationAPHN. Shortness of breath. Ednin Hamzah CEO, Hospis Malaysia.
APHN Shortness of breath Ednin Hamzah CEO, Hospis Malaysia ednin@hospismalaysia.org What is it? a subjective experience of difficult and uncomfortable breathing American Thoracic Society What do the patients
More informationPalliative Care and End of Life Care
Palliative Care and End of Life Care 8/2012 Palliative Care Palliative care is specialized medical care for people with serious illness. This type of care is focused on providing patients with relief from
More informationEnd of life prescribing guidance
End of life prescribing guidance Introduction This guidance has been prepared to ASSIST IN DECISION MAKING for the prescribing and monitoring of medicines useful in the management of symptoms commonly
More informationAnticipatory prescribing and end of life considerations. Dr Stephanie Lippett
Anticipatory prescribing and end of life considerations Dr Stephanie Lippett contents Pain Restlessness/agitation Nausea/vomiting Secretions Syringe driver Anticipatory prescribing Important things to
More informationSymptom Management Guidelines for End of Life Care
Symptom Management Guidelines for End of Life Care The following pages are guidelines for the management of common symptoms in the last few days of life. General principles: 1. Consider how symptoms can
More informationSYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL
SYMPTOM MANAGEMENT GUIDANCE FOR PATIENTS RECEIVING PALLIATIVE CARE AT ROYAL DERBY HOSPITAL If a patient is believed to be approaching the end of their life, medication should be prescribed in anticipation
More informationJ Clin Oncol 23: by American Society of Clinical Oncology INTRODUCTION
VOLUME 23 NUMBER 22 AUGUST 1 2005 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Rapid Switching Between Transdermal Fentanyl and Methadone in Cancer Patients Sebastiano Mercadante, Patrizia
More informationDementia and End of Life Care
Dementia and End of Life Care Dr. Tim Hiebert Rachael Mierke March 4, 2015 Learning Objectives People will have a better understanding/appreciation: Of end of life (EOL) care for people with dementia How
More informationSymptom Control and End of Life Care
Symptom Control and End of Life Care MND Special Interest Groups Workshop Dr Cynthia Parr Staff Specialist in Palliative Medicine 12 September 2013 The best test of a physician s suitability for the specialized
More informationPalliative Sedation. B. Craig Weldon, MD. That sweet, deep sleep, so close to tranquil death. The Aeneid, Virgil [70-19 B.C.E]
Palliative Sedation That sweet, deep sleep, so close to tranquil death. The Aeneid, Virgil [70-19 B.C.E] B. Craig Weldon, MD 5 th Annual UNC-Duke-Wake Forest Pediatric Anesthesiology Conference 25 August
More informationBarb Supanich, RSM, MD, FAAHPM Medical Director, Palliative Care Team September 9, 2010
Barb Supanich, RSM, MD, FAAHPM Medical Director, Palliative Care Team September 9, 2010 Learner Goals Define Palliative Sedation Identify at least two pertinent Ethical Issues for the patient, family and
More informationPAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE
PAIN AND SYMPTOM MANAGEMENT GUIDANCE IN THE LAST DAYS OF LIFE Reference: DCM029 Version: 1.1 This version issued: 07/06/18 Result of last review: Minor changes Date approved by owner (if applicable): N/A
More informationPalliative Care. Anticipatory Prescribing Guidelines & June Gippsland Region Palliative Care Consortium Clinical Practice Group
Palliative Care Anticipatory Prescribing Guidelines June 2016 Gippsland Region Palliative Care Consortium Clinical Practice Group Policy No. Title Keywords Ratified GRPCC-CPG008_1.1_2016 Anticipatory Prescribing
More informationPalliative care in long-term conditions Scottish Palliative Care Pharmacists Association
Palliative care in long-term conditions 2011 2012 Scottish Palliative Care Pharmacists Association Aims & Objectives To explore symptoms, general management principles and appropriate palliative treatment
More informationFor patients and their carers this means smoother symptom control, better support in a crisis, and avoidance of admission if that is their choice.
Bedfordshire Palliative Care Palliative Care Medicines Guidance This folder has been produced to support professionals providing palliative care in any setting. Its aim is to make best practice in palliative
More information4/10/2018. Preparing for Death. Describe a Recent Death You Have Observed. The Nurse, Dying and Death
Preparing for Death Core Curriculum FINAL HOURS CARLA JOLLEY MN, ARNP, AOCN, ACHPN WHIDBEYHEALTH PALLIATIVE CARE JOLLEC@WHIDBEYHEALTH.ORG Everyone dies Advance care planning Recognizing the transition
More informationBreathlessness in advanced disease. February 2017
Breathlessness in advanced disease February 2017 Breathlessness Managing breathlessness in primary care Chronic breathlessness Acute exacerbation of breathlessness Breathlessness at end of life Breathlessness
More informationNeonatal & Pediatric Palliative Care
Neonatal & Pediatric Palliative Care Christopher A. Collura, MD North Regional Respiratory Care Conference April 16 th, 2018 2015 MFMER slide-1 Disclosures Relevant financial relationship(s) with industry
More informationDelirium and Dementia
Delirium and Dementia Elder Friendly Care in Acute Care Seniors Health Strategic Clinical Network Acute Care Stress Blender Poor Poor sleep At-Risk Older Adult TREAT CAUSE immediately & aggressively. Increased
More informationDELIRIUM IN ICU: Prevention and Management. Milind Baldi
DELIRIUM IN ICU: Prevention and Management Milind Baldi Contents Introduction Risk factors Assessment Prevention Management Introduction Delirium is a syndrome characterized by acute cerebral dysfunction
More informationCare of dying adults in the last days of life. Improving care at the very end of life.
Care of dying adults in the last days of life Improving care at the very end of life. Foreword We will all experience death, whether it is our own or that of a loved one. The bereaved person s perception
More informationRespiratory Issues at End-of-Life. Jerry Boltz, FNP January 27, L N E C Geriatric Curriculum
Respiratory Issues at nd-of-life Jerry Boltz, FNP January 27, 2012 L N C Geriatric Curriculum nd-of-life Nursing ducation Consortium Module 3: Nonpain Symptoms at the nd of Life Part I Common Respiratory
More informationGUIDELINES & PROTOCOLS
GUIDELINES & PROTOCOLS ADVISORY COMMITTEE Palliative Care for the Patient with Incurable Cancer or Advanced Disease Part 2: Pain and Symptom Management Dyspnea Effective Date: September 30, 2011 Scope
More informationAgency 71. Kansas Dental Board (Authorized by K.S.A and (Authorized by K.S.A and
Agency 71 Kansas Dental Board Articles 71-4. CONTINUING EDUCATION REQUIREMENTS. 71-5. SEDATIVE AND GENERAL ANAESTHESIA. 71-11. MISCELLANEOUS PROVISIONS. Article 4. CONTINUING EDUCATION REQUIREMENTS 71-4-1.
More informationQuality of Life (F309 End of Life) Surveyor Train the Trainer: Interpretive Guidance Investigative Protocol
483.25 Quality of Life (F309 End of Life) Surveyor Train the Trainer: Interpretive Guidance Investigative Protocol 2 483.25 End of Life Each resident must receive and the facility must provide the necessary
More informationPalliative Care and the Critical Role of the Pharmacist. Arti Thakerar Education/ Palliative Care Peter MacCallum Cancer Centre
Palliative Care and the Critical Role of the Pharmacist Arti Thakerar Education/ Palliative Care Peter MacCallum Cancer Centre Overview What is palliative care Role of a pharmacist in palliative care Issues
More informationPHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS
PHARMACY SERVICE ARRANGEMENTS FOR THE SUPPLY OF PALLIATIVE CARE SYRINGES AND MEDICINES FOR COMMUNITY PATIENTS The benefits of prefilled syringes for palliative care from the hospital pharmacy service In
More informationIPRAVENT Rotacaps (Ipratropium bromide)
Published on: 10 Jul 2014 IPRAVENT Rotacaps (Ipratropium bromide) Composition IPRAVENT Rotacaps Each capsule contains: Ipratropium Bromide BP, equivalent to Ipratropium Bromide (anhydrous) 40 mcg Excipient..q.s.
More informationDifficult weaning from mechanical ventilation
Difficult weaning from mechanical ventilation Paolo Biban, MD Director, Neonatal and Paediatric Intensive Care Unit Division of Paediatrics, Major City Hospital Azienda Ospedaliera Universitaria Integrata
More informationCHAPTER 11. General and Local Anesthetics. Anesthetics. Anesthesia. Eliza Rivera-Mitu, RN, MSN NDEG 26 A
CHAPTER 11 General and Local Anesthetics Eliza Rivera-Mitu, RN, MSN NDEG 26 A Anesthetics Agents that depress the central nervous system (CNS) Depression of consciousness Loss of responsiveness to sensory
More informationOpioids silent killers?
Opioids silent killers? Jason Boland Senior clinical lecturer and honorary consultant in palliative medicine Hull York Medical School and North East Lincolnshire, UK Does it depend on the situation? Opioids
More informationSYMPTOM CONTROL IN THE LAST DAYS OF LIFE. Bradford, Airedale, Wharfedale & Craven
Bradford, Airedale, Wharfedale & Craven Managed Clinical Network SYMPTOM CONTROL IN THE LAST DAYS OF LIFE Guidelines for Healthcare Professionals Bradford, Airedale, Wharfedale & Craven Signs and symptoms
More informationCOMPENDIA TRANSPARENCY TRACKING FORM. Ketamine hydrochloride. Cancer pain, Opioid therapy; Adjunct
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Ketamine hydrochloride INDICATION: Cancer pain, Opioid therapy; Adjunct COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide criteria used to evaluate/prioritize the
More informationGUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT (estimated glomerular filtration rate<30)
GUIDELINES FOR PRESCRIBING AT THE END OF LIFE FOR PATIENTS WITH RENAL IMPAIRMENT These guidelines have been produced in collaboration with Dr Lucy Smyth, Consultant in Renal Medicine, Royal Devon and Exeter
More informationPharmacotherapy for Alcohol Dependence
Evidence Report/Technology Assessment: Number 3 Pharmacotherapy for Alcohol Dependence Summary Under its Evidence-Based Practice Program, the Agency for Health Care Policy and Research (AHCPR) is developing
More informationNebulized Versus Subcutaneous Morphine for Patients with Cancer Dyspnea: A Preliminary Study
Vol. 29 No. 6 June 2005 Journal of Pain and Symptom Management 613 Clinical Note Nebulized Versus Subcutaneous Morphine for Patients with Cancer Dyspnea: A Preliminary Study Eduardo Bruera, MD, Raul Sala,
More informationalone seen a corpse. The case of Monica was very different. For the first time, I became
Maia Lauria Issues of Life and Death Ethical Reflection Hospice and Palliative Care I first stumbled upon the issue of palliative care during a particularly hard time in my life. I was twenty years old,
More informationIs it palliative sedation or just good symptom management?
Is it palliative sedation or just good symptom management? Cautions, Concerns, Indications Geoff Davis M.D. Nov 2010 Objectives Explain the Principle of Double Effect and list its conditions for an appropriate
More informationEAST LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE
EAST LANCASHIRE SPECIALIST PALLIATIVE CARE TEAM EAST LANCASHIRE GUIDELINES FOR THE MANAGEMENT OF SYMPTOMS IN THE LAST DAYS OF LIFE Reviewed and updated August 2009 Next review date August 2011 Approved
More informationGestione della dispnea nell insufficienza respiratoria end-stage
Gestione della dispnea nell insufficienza respiratoria end-stage Salvatore M. Maggiore, MD, PhD salvatore.maggiore@unich.it Anesthesia and Intensive Care SS. Annunziata Hospital Gabriele d Annunzio University
More informationPrognostic Factors of Survival in Patients With Advanced Cancer Admitted to Home Care
56 Journal of Pain and Symptom Management Vol. 45 No. 1 January 2013 Original Article Prognostic Factors of Survival in Patients With Advanced Cancer Admitted to Home Care Sebastiano Mercadante, MD, Alessandro
More informationPATIENTS WHO WITHDRAW FROM DIALYSIS. Dr Katalin Urban Palliative Care Specialist Greenwich Hospital
PATIENTS WHO WITHDRAW FROM DIALYSIS Dr Katalin Urban Palliative Care Specialist Greenwich Hospital Registrar project for FRACP Title: Patients who withdraw from dialysis in a Sydney centre with Palliative
More informationSymptom Management in the Non-Verbal Patient at the End of Life Laura Carmon, ANP-BC
Symptom Management in the Non-Verbal Patient at the End of Life Laura Carmon, ANP-BC 2017 NPSS Asheville, NC Objectives The learner will recognize non-verbal signs and symptoms commonly seen at the EOL.
More information